对接受血管紧张素转换酶抑制剂治疗的重度心力衰竭患者长期口服昔莫洛尔的疗效和安全性。
The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
作者信息
Pouleur H, Hanet C, Rousseau M F
机构信息
Division of Cardiology, University of Louvain, Brussels, Belgium.
出版信息
Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):82S-83S. doi: 10.1111/j.1365-2125.1989.tb03581.x.
Xamoterol 200 mg twice daily was given for 2 months to nine patients with severe heart failure already being treated with angiotensin converting enzyme (ACE) inhibitors. Left ventricular end-diastolic pressure fell from 28 to 13 mmHg and end-systolic volume fell from 115 to 106 ml m-2; indices of contractility improved and ejection fraction rose from 33 to 38%. The time constant of ventricular relaxation, T1, improved from 62 to 44 ms. Exercise tolerance improved. Thus, in this group of patients with severe heart failure, xamoterol produced benefits in systolic and diastolic function. There were no adverse effects.
对9名已经接受血管紧张素转换酶（ACE）抑制剂治疗的重度心力衰竭患者，给予每日两次200毫克的xamoterol，持续2个月。左心室舒张末期压力从28毫米汞柱降至13毫米汞柱，收缩末期容积从115毫升/平方米降至106毫升/平方米；收缩性指标改善，射血分数从33%升至38%。心室舒张时间常数T1从62毫秒改善至44毫秒。运动耐量提高。因此，在这组重度心力衰竭患者中，xamoterol对收缩和舒张功能均产生了有益作用。未出现不良反应。
Zotero 插件